(Bloomberg) -- Johnson & Johnson is withdrawing a device to treat debilitating acid reflux disease from markets outside the US, a move surgeons warned would set back the available treatment options for sufferers by more than a decade and also impact lung transplant patients. Sales of the Linx Reflux Management System will be stopped outside the US from the end of March, the company said in a letter to doctors dated Sept. 17 seen by Bloomberg. J&J confirmed it was stopping sales in “certain countries,” bas ...